Bruker Corporation
NASDAQ:BRKRMedical - Devices
-$1.07 today
- Market cap
- $9.66B
- Beta
- 1.30
- P/E (TTM)
- -718.1
- EPS (TTM)
- -$0.08
- Dividend yield
- 0.37%
Volume 1.73M
Average 2.41M
BRKR Total Debt
Short-term and long-term borrowings combined.
Bruker CorporationNASDAQ: BRKR
Total Debt · Q2 FY2026 · quarter ended Jun 2026
Total debt falls 21.3% from a year ago
Total debt stood at $1.92B at the end of Q2 FY2026, down 21.3% from a year earlier and up 14.6% from the prior quarter. Over 3 fiscal years it compounded at +17.2% a year.
Context
- Total debt amounted to 31.6% of total assets at the end of Q2 FY2026, down 6.8 pp from a year earlier.
- Total debt increased in 2 of the last 3 fiscal years.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -21.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 2.04B USD
- Year-over-year change
- -9.0%
- 4-year CAGR
- +10.0%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.04B | -9.0% |
| FY2024 | 2024-12-31 | 2.25B | +62.8% |
| FY2023 | 2023-12-31 | 1.38B | +8.6% |
| FY2022 | 2022-12-31 | 1.27B | -8.9% |
| FY2021 | 2021-12-31 | 1.39B | — |
Total Debt vs competitors
How BRKR compares with its peers on the latest reported figures
- BRKR's Jun 2026 total debt of $1.92B is the 7th highest of the 11 companies compared; the peer median is $2.73B.
- Its year-over-year change of -21.3% is the 10th highest of 11, against a peer median of +7.2%.
- Total debt amounts to 31.6% of total assets for BRKR, versus a peer median of 28.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $41.37B | +15.9% | +3.0% | 36.2% | |
| Sep 2026 | $26.48B | +57.1% | -3.7% | 28.4% | |
| Jul 2026 | $5.25B | +241.5% | -3.6% | 21.2% | |
| Jul 2026 | $3.95B | +15.8% | +6.6% | 28.3% | |
| Jul 2026 | $3.34B | -1.0% | -8.5% | 27.7% | |
| Jun 2026 | $2.11B | -3.3% | +3.2% | 57.5% | |
| Jun 2026 | $1.92B | -21.3% | +17.2% | 31.6% | |
| Jun 2026 | $1.64B | +13.8% | -6.5% | 27.9% | |
| Jun 2026 | $1.2B | -14.4% | +3.3% | 11.7% | |
| Mar 2026 | $703.39M | +0.6% | -7.1% | 89.9% | |
| Sep 2026 | $285.56M | -27.6% | -14.0% | 10.8% | |
| Peer median (excluding BRKR) | $2.73B | +7.2% | -3.6% | 28.1% | |
Competitors are the stored peer set for BRKR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.07B | 645.5M | 488.3M | 183.4M | 298.8M |
| Short-term Investments | 100M | 0 | 0 | 0 | 0 |
| Net Receivables | 416.9M | 595.3M | 621.8M | 701.2M | 736M |
| Inventory | 710.1M | 800.1M | 968.3M | 1.07B | 1.09B |
| Other Current Assets | 176.6M | 29M | 30.3M | 39.6M | 47.9M |
| Total Current Assets | 2.47B | 2.11B | 2.16B | 2.05B | 2.21B |
| Property, Plant & Equipment (Net) | 466M | 538.2M | 691.4M | 814.8M | 910.6M |
| Goodwill | 339.5M | 457.6M | 582.6M | 1.51B | 1.55B |
| Intangible Assets | 211.8M | 270.9M | 330.5M | 912.5M | 899.6M |
| Long-term Investments | 0 | 0 | 0 | 0 | 8.2M |
| Tax Assets | 90.1M | 76.8M | 297.2M | 286.2M | 421.7M |
| Other Non-current Assets | 70.8M | 155.1M | 184M | 232.7M | 241.1M |
| Total Non-current Assets | 1.18B | 1.5B | 2.09B | 3.75B | 4.03B |
| Total Assets | 3.65B | 3.61B | 4.25B | 5.81B | 6.24B |
| Account Payables | 147.4M | 178.4M | 202.7M | 234.1M | 215.9M |
| Short-term Debt | 112.4M | 18.7M | 121.2M | 32.5M | 51.8M |
| Tax Payables | 90.5M | 104M | 157.4M | 142.5M | 0 |
| Deferred Revenue | 335.9M | 370.2M | 400M | 438.2M | 441.3M |
| Other Current Liabilities | 156.4M | 159.9M | 218.3M | 300.3M | 302.8M |
| Total Current Liabilities | 938.5M | 914.3M | 1.2B | 1.28B | 1.28B |
| Long-term Debt | 1.22B | 1.2B | 1.16B | 2.06B | 1.69B |
| Deferred Tax Liabilities | 46M | 62.3M | 67.7M | 118.5M | 112.5M |
| Deferred Revenue (Non-current) | 50.2M | 101.6M | 91.5M | 100M | 109.1M |
| Other Non-current Liabilities | 266.9M | 166.5M | 240.2M | 311M | 239.2M |
| Total Non-current Liabilities | 1.63B | 1.57B | 1.63B | 2.71B | 2.45B |
| Total Liabilities | 2.57B | 2.48B | 2.84B | 3.99B | 3.73B |
| Common Stock | 1.7M | 1.7M | 1.7M | 1.8M | 1.8M |
| Retained Earnings | 1.66B | 1.93B | 2.32B | 2.41B | 2.36B |
| Accumulated OCI | (8.2M) | 14.8M | 6M | (103.5M) | (79.5M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 14.3M | 18M | 36.1M | 34M | 53.8M |
| Total Equity | 1.08B | 1.13B | 1.41B | 1.82B | 2.51B |
| Total Debt | 1.39B | 1.27B | 1.38B | 2.25B | 2.04B |
| Net Debt | 325.7M | 624.9M | 891.3M | 2.06B | 1.74B |
Bruker Corporation
NASDAQ:BRKR
Intrinsic Alpha fair value
Locked
Current Price
$63.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.